SEYED EBRAHIM KASSAIAN to Drug-Eluting Stents
This is a "connection" page, showing publications SEYED EBRAHIM KASSAIAN has written about Drug-Eluting Stents.
Connection Strength
1.389
-
Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study. Tex Heart Inst J. 2016 Apr; 43(2):126-30.
Score: 0.453
-
Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions. Cardiovasc J Afr. 2010 Nov-Dec; 21(6):311-5.
Score: 0.311
-
Predictors of major adverse cardiac events following elective stenting of large coronary arteries. Indian Heart J. 2018 Jan - Feb; 70(1):20-23.
Score: 0.123
-
Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patients with coronary artery disease: data from the THCRIC registry. Ther Adv Cardiovasc Dis. 2016 Aug; 10(4):206-13.
Score: 0.112
-
Selective versus exclusive use of drug-eluting stents in treating multivessel coronary artery disease: a real-world cohort study. Tex Heart Inst J. 2014 Oct; 41(5):477-83.
Score: 0.102
-
On-label and off-label use of drug-eluting stents: comparison of short- and long-term outcomes. Tex Heart Inst J. 2012; 39(1):24-9.
Score: 0.084
-
In-hospital and mid-term clinical outcomes after percutaneous coronary intervention with the use of sirolimus- or paclitaxel-eluting stents. Kardiol Pol. 2009 Dec; 67(12):1344-50.
Score: 0.073
-
Clinical outcomes of drug-eluting stents compared with bare metal stents in our routine clinical practice. Hellenic J Cardiol. 2008 May-Jun; 49(3):132-8.
Score: 0.065
-
Short- and long-term outcomes of percutaneous coronary intervention in patients with low, intermediate and high ejection fraction. Cardiovasc J Afr. 2008 Jan-Feb; 19(1):17-21.
Score: 0.064